{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-120348","form_type":"8-K","ticker":null,"cik":"0001600132","company_name":"Bellerophon Therapeutics, Inc.","filed_at":"2023-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.713622+00:00","generated_at":"2026-06-07T22:41:04.247214+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bellerophon appoints Craig Jalbert President/principal officer amid wind-down; CEO leaves Nov 15","bullets":["CEO Peter Fernandes and VP Parag Shah separated effective Nov 15, 2023, per previously disclosed separation agreements.","Craig Jalbert appointed President, Treasurer, Corporate Secretary, principal executive/financial/accounting officer, and director.","Jalbert, a distressed-business specialist at Verdolino & Lowey, will be compensated $10k/month pre-dissolution, then $50k/year for three years post-dissolution.","Compensation structure is contingent on stockholder approval of dissolution and board decision to implement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-120348","json":"https://secwatch.observer/filing/0001104659-23-120348.json","markdown":"https://secwatch.observer/filing/0001104659-23-120348.md","text":"https://secwatch.observer/filing/0001104659-23-120348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/tm2331228d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T22:41:04.247214+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7839b5751e","claim":"Craig Jalbert was appointed as Director at Bellerophon Therapeutics, Inc..","evidence_excerpt":"On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"861d0a10ef","claim":"Craig Jalbert was appointed as President at Bellerophon Therapeutics, Inc..","evidence_excerpt":"On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the Company's President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"abfae72d06","claim":"Peter Fernandes departed as Chief Executive Officer at Bellerophon Therapeutics, Inc..","evidence_excerpt":"the board of directors of the Company (the “Board”) set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ef8bf475c1","claim":"Parag Shah departed as Vice President of Business Operations at Bellerophon Therapeutics, Inc..","evidence_excerpt":"the board of directors of the Company (the “Board”) set November 15, 2023 as the separation date for the employment of each of Dr. Fernandes and Mr. Shah.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600132/000110465923120348/0001104659-23-120348-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Vice President of Business Operations"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}